Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- PhytoMedical's In Vivo Toxicity and Efficacy Tests on Human Colon Cancer Deliver Promising Results
- Anti-cancer compound exhibits significant efficacy and toxicity values leading to further development PRINCETON, N.J. -- PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced the results of its anti-cancer compound in vivo toxicity and efficacy tests on HCT116 human colon cancer cells was successful. "I am encouraged by the...
- Research articles 2008-10-27
- RegeneRx Sponsors "Walk a Mile in My Shoes" for National Epidermolysis Bullosa Awareness Week
- BETHESDA, Md. -- REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it is a major sponsor of "Walk a Mile in My Shoes," the signature event of National Epidermolysis Bullosa EB Awareness Week. The "Walk a Mile in My Shoes" program coordinates events that include rallies, meetings and walk-a-thons in...
- Research articles 2008-10-24
- RegeneRx President and CEO to Speak at 7th Annual BIO Investor Forum
- BETHESDA, Md. -- REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) announced today that J.J. Finkelstein, RegeneRx's president and chief executive officer, will present a company update at the 7th Annual BIO Investor Forum in San Francisco, CA, on Thursday, October 30, 2008 at 2:00 p.m. ET. To listen and view the presentation investors...
- Research articles 2008-10-22
- Upstream Biosciences' Potential Tropical Disease Treatments Demonstrate Promising Signs of Efficacy at McGill University
- Upstream Biosciences Inc. (OTCBB: UPBS) today announced that its second generation of novel antiparasitic agents demonstrated in vitro efficacy against both Leishmaniasis and Trypanosomiasis. Upstream's novel compounds were tested by Dr. Armando Jardim at the Institute of Parasitology of McGill University in Montreal, Quebec, Canada. Upstream continues to collaborate with...
- Research articles 2008-10-07
- RegeneRx to Develop RGN-457 for Cystic Fibrosis
- RegeneRx Seeking Strategic Partnership to Address CF in U.S. and Europe BETHESDA, Md. -- REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it is seeking a strategic partner to assist in the development of RGN-457 for the treatment of cystic fibrosis CF. RGN-457 is based on thymosin beta 4...
- Research articles 2008-10-01
- RegeneRx Completes Patient Enrollment of First Phase II Clinical Trial
- BETHESDA, Md. -- REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it completed enrollment of its first of four ongoing Phase II clinical trials. The trial is a double-blind, placebo-controlled, dose-escalating clinical trial evaluating the safety and efficacy of the Company's topical drug candidate, RGN-137, in seventy-two patients with pressure...
- Research articles 2008-08-20
- Titan Pharmaceuticals Announces Spheramine® Presentations at 12th International Congress of Parkinson's Disease and Movement Disorders
- Five-Year Update of Pilot Study Shows Spheramine Reduces Severity and Frequency of Parkinson's Symptoms While Also Improving Health-Related Quality of Life CHICAGO & SOUTH SAN FRANCISCO -- Titan Pharmaceuticals, Inc. (AMEX:TTP) today announced that Spheramine[R], the company's novel cell-based therapy being developed in collaboration with Bayer Schering Pharma AG...
- Research articles 2008-06-24
- SPEEDEL REPORTS ON DATA PUBLISHED AT HYPERTENSION 2008 MEDICAL CONGRESS
- Speedel Holding Ltd. (SWX: SPPN) today announced that data for two of its developmental product candidates were presented at Hypertension 2008, the joint meeting of the International Society of Hypertension ISH and the European Society of Hypertension ESH in Berlin (14- 19 June 2008). Results from the Phase IIa proof-of-concept...
- Research articles 2008-06-19
- Cleveland BioLabs to Submit Protectan CBLB502 for BARDA BAA for Development of Therapies to Protect Civilian Population From Radiation Exposure
- Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it will submit Protectan CBLB502 for the Broad Agency Announcement BAA soliciting research and development proposals for "Therapies for Hematopoietic Syndrome, Bone Marrow Stromal Cell Loss, and Vascular Injury Resulting from Acute Exposure to Ionizing Radiation" published on March 6, by the...
- Research articles 2008-04-09
- Healthcare Stocks to Watch: HSXI, HEPH, OPXA, WPI.
- M2 PRESSWIRE-12 March 2008-Financialbusinessnews.us: Healthcare Stocks to Watch: HSXI, HEPH, OPXA, WPIC1994-2008 M2 COMMUNICATIONS LTD RDATE:12032008 Boston, MA -- HealthSonix, Inc. (OTC: HSXI); Hollis-Eden Pharmaceuticals, Inc. (NASDAQ: HEPH); Opexa Therapeutics, Inc. (NASDAQ: OPXA); Watson Pharmaceuticals, Inc. (NYSE: WPI) ...
- Research articles 2008-03-12
- PURE Bioscience Announces Licensing and Distribution Agreement with Mid-Continent Packaging, Inc. for SDC-based Private Label Hard Surface Disinfectant
- Biosilver[TM] Disinfectant Targeted to Direct-to-Consumer Television Shopping Networks SAN DIEGO -- PURE Bioscience (OTCBB: PURE) today announced it has granted a license to privately held Mid-Continent Packaging, Inc., a company with over 45 years experience in contract chemical packaging, for blending, packaging and distribution of PURE's patented silver dihydrogen...
- Research articles 2008-03-06
- Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment.
- CALGARY, Canada, January 7 /PRNewswire/ -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ('Oncolytics') reported today that a research group led by Dr. Richard Vile of the Mayo Clinic College of Medicine in Rochester, Minnesota, published the results of its ...
- Research articles 2008-01-07
- Lunchtime Investor Focus.
- M2 PRESSWIRE-4 January 2008-Businessnetwire.us: Lunchtime Investor FocusC1994-2008 M2 COMMUNICATIONS LTD RDATE:04012008 New York, NY -- BusinessNetWire's "Investor's Update" Focuses on the Following Companies: Wellco Energy Services Trust (TSX: WLL.UN); Paladin Labs Inc. (TSX: PLB); Cleveland...
- Research articles 2008-01-04
- Cleveland BioLabs Not Selected for Defense Contract Award
- Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it was informed by the Department of Defense DoD that Protectan CBLB502, the Company's candidate for the treatment of gastrointestinal GI effects of acute radiation syndrome was not selected for award under the request for proposal RFP No. W9113M-07-R-0002, entitled, "Medical Radiation...
- Research articles 2008-01-04
- USA: DYNETICS AWARDED CONTRACT FOR SYNERGISTIC ELECTRONICS WARFARE.
- Dynetics, Incorporated of Huntsville, Ala., is being awarded a contract for $24,000,000. This action provides for Synergistic Electronics Warfare Program renamed Multi-Yield RFCM Investing and Development to develop advanced Electronic Warfare techniques and technologies that extended USAF radio frequency battle-space access against advanced Integrated Air...
- Research articles 2007-12-20
- DYNETICS AWARDED CONTRACT FOR SYNERGISTIC ELECTRONICS WARFARE
- Dynetics, Incorporated of Huntsville, Ala., is being awarded a contract for $24,000,000. This action provides for Synergistic Electronics Warfare Program renamed Multi-Yield RFCM Investing and Development to develop advanced Electronic Warfare techniques and technologies that extended USAF radio frequency battle-space access against advanced Integrated Air Defense System and the asymmetrical...
- Research articles 2007-12-20
- Clean Control Corporation's Germ Control 24™ Featured on Nationally Televised "Geraldo at Large"
- SDC-Based Disinfectant Available at Leading Home Improvement Retailer WARNER ROBINS, Ga. -- Clean Control Corporation, manufacturer of Germ Control 24[TM], a revolutionary disinfectant containing PURE Bioscience's (OTCBB:PURE) patented silver dihydrogen citrate SDC, announced today that Germ Control 24 was discussed during a live interview on the nationally televised program...
- Research articles 2007-11-21
- Media Alert: Tommy G. Thompson Speaks Out Against Misinformation and Lack of Public Education Regarding MRSA "Superbug"
- Proven Method of Prevention Being Overlooked SAN DIEGO -- "Recent media reports are misleading and grossly underestimate both the ways in which MRSA can be transmitted and the preventative measures currently available," according to Tommy G. Thompson, former U.S. Secretary of Health and Human Services and former four-term Governor...
- Research articles 2007-11-13
- ONDINE BIOPHARMA CORPORATION - Presentation - European Society of Photobiology.
- Data Demonstrating Efficacy of PeriowaveTM Photodisinfection Therapy for the Treatment of Gum Disease Presented at 12th Congress of the European Society of Photobiology - Presentation by Professor Michael Wilson highlights success of Ondine's clinical trials -...
- Research articles 2007-09-19
- AtheroGenics Announces New ARISE Diabetes Data on AGI-1067 Presented at the European Society of Cardiology Congress 2007
- AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced the presentation of new scientific data from its ARISE Phase III clinical outcomes study of its lead oral anti-diabetic drug candidate, AGI-1067, at the European Society of Cardiology Congress 2007. The data were...
- Research articles 2007-09-05
- << Previous
- page 1 of 5
- Next >>
Content Types
Refining Tags
- Company (25 results)
- Patient (17 results)
- HEALTHCARE (15 results)
- Government (14 results)
- U.S. Congress (11 results)
- FDA (10 results)
- Finance (8 results)
- Nasdaq Stock Market Inc. (8 results)
- SOFTWARE (7 results)
- MARKETING (7 results)
- U.S. Environmental Protection Agency (7 results)
- SEC (6 results)
- Business Wire (6 results)
- Dr. (6 results)
- SECURITY (5 results)
- Benefits (5 results)
- therapy (5 results)
- investor (5 results)
- Biotechnology (4 results)
- Manufacturing (4 results)
- Medication (4 results)
- U.S. (4 results)
- Compound (4 results)
- bacteria (3 results)
- technique (3 results)
- Leadership (3 results)
- U.S. Department of Health and Human Services (3 results)
- Productivity (3 results)
- agreement (3 results)
- Internet (3 results)
- Call Transcript (3 results)
- Earnings (3 results)
- HARDWARE (3 results)
- Investment (3 results)
- Frost & Sullivan (3 results)
- Strategy (3 results)
- agent (3 results)
- Seeking Alpha (3 results)
- radiation (3 results)
- PURE Bioscience (3 results)
- RegeneRX Biopharmaceuticals Inc. (3 results)
